M
utations and translocations in genes encoding epigenetic factors, such as histone lysine methyltransferases (KMTs) and lysine demethylases (KDMs), are a common mechanism that drives tumorigenesis [1] [2] [3] [4] [5] [6] . Thus, both KMTs and KDMs are potential therapeutic targets in human cancers [7] [8] [9] [10] . On the basis of primary amino acid sequence and substrate specificity, KMTs are divided into six subfamilies 11 . SET1A, SET1B, MLL1, MLL2, MLL3 and MLL4, which belong to the KMT2 family, catalyze mono-, diand trimethylation of H3K4 (H3K4me1, H3K4me2 and H3K4me3, respectively) and are proposed to be involved in the positive regulation of gene transcription 12, 13 . This family of enzymes was initially biochemically isolated from yeast in a macromolecular complex named 'complex of proteins associated with SET1' (COMPASS) 13, 14 . Genome-wide sequencing of cancer cells has identified frequent mutations within genes encoding the COMPASS subunits, suggesting that misregulation of the subunit activities has an important role in pathogenesis 1, 15 . For instance, chromosomal translocations generate MLL fusion proteins that constitutively activate the posterior HOXA cluster, resulting in aberrant self-renewal of hematopoietic progenitors and the development of leukemia 16, 17 . In diffuse large B cell lymphoma and follicular lymphoma, MLL4 (also known as KMT2D) functions as a tumor suppressor, and mutations within the sequence encoding its catalytic domain promote lymphomagenesis 18, 19 .
Unlike other COMPASS family members, which catalyze H3K4me3 formation 13 , MLL3 and MLL4 catalyze H3K4me1 formation at enhancer sequences 20, 21 and are among the most frequently altered histone modifiers in human cancers 22 . MLL3 mutations are detected in a broad spectrum of tumors, including hepatocellular carcinoma 23 , breast cancer 24 , colon cancer 25 bladder cancer 26 , myelodysplastic syndromes and acute myeloid leukemia (AML) 27 . Subunits within the MLL3 COMPASS, such as PTIP 28 and UTX 29 , are also involved in human cancer pathogenesis. Although a large number of MLL3 mutations have been identified, the molecular consequence of these mutations with respect to MLL3's functional domains remains unexplored. Here we identify an MLL3 mutational hotspot located within the sequence encoding the first PHD repeats, and we establish a functional link between these mutations and the BAP1 histone deubiquitination signaling pathway and provide a targeted therapeutic approach by resetting the balanced state of the Polycomb and COMPASS families in the regulation of gene expression.
Results

MLL3 COMPASS uniquely associates with the BAP1 complex.
Genome-wide studies of diverse human cancers have identified frequent mutations in the gene encoding the H3K4 monomethyltransferase, MLL3 15 . To understand the global mutation status of MLL3
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NATURe MeDiCiNe in human cancer, we retrieved data from The Cancer Genome Atlas (TCGA) database and identified two mutational hotspots within the sequence encoding the MLL3 amino (N)-terminal PHD finger repeats ( Fig. 1a and Supplementary Fig. 1a-h ). By comparison, there were no obvious mutational hotspots within the sequence encoding the closely related COMPASS family member, KMT2D (also known as MLL4) (Fig. 1b) . Given the prevalence of cancer-associated mutations in the sequence encoding the MLL3 PHD, we hypothesized that the PHD repeats could mediate important protein-protein interactions that might provide insight toward targeted therapeutic approaches for MLL3-mutation-induced cancers. To test this hypothesis, we expressed and purified the first 1,200 amino acids of the MLL3 N-terminal domain (MLL3-NTD), which contained these mutational hotspots, from HEK293T cells (Fig. 1c, top) . Mass spectrometry (MS) analysis of MLL3-NTD pulldowns demonstrated that the BAP1 complex (Supplementary Table 1 )-which contains ASXL1, ASXL2, ASXL3, KDM1B, HAX1 and OGT-co-purified with this portion of MLL3 (Fig. 1c, bottom) , and the stoichiometry of these MLL3-NTD interactors was calculated 30 ( Supplementary Fig. 1i ). Western blotting analysis confirmed an interaction between the BAP1 complex and MLL3-NTD (Fig. 1d) .
To investigate whether endogenous MLL3 also interacted with BAP1, we immunoprecipitated the MLL3, MLL4, SET1A and SET1B components of the COMPASS family from HEK293T cells using antibodies specific for each methyltransferase ( Fig. 1e and Supplementary Fig. 1j ). BAP1 was exclusively detected in MLL3-specific immunoprecipitates, whereas UTX, a component of the MLL3 and MLL4 COMPASS 13 complexes, was detected in both MLL3-specific and MLL4-specific immunoprecipitates (Fig. 1e) . By contrast, RBBP5, a common subunit of all COMPASS complexes, was detected in all of the immunoprecipitation (IP) reactions (Fig. 1e) . We performed reciprocal IP reactions using a BAP1-specific antibody and found that, of the COMPASS family members, only MLL3 was enriched (Fig. 1f) . The interaction between BAP1 and MLL3 was also confirmed in two additional cell lines ( Supplementary Fig. 1k ). Thus, the BAP1 complex is a unique interacting partner of MLL3 COMPASS, and this interaction is mediated through the N-terminal domain of MLL3 containing the PHD repeats.
Cancer-associated mutations in the PHD-encoding region of MLL3 disrupt BAP1 binding. The discovery of two mutational hotspots within the region encoding the MLL3-PHD repeats (hereafter referred to as MLL3 PHD ) prompted us to hypothesize that MLL3 PHD mutations might correlate with cancer survival. To test this hypothesis, we separated MLL3 mutations into those that occurred either inside or outside of the PHD-repeat-encoding sequence ( Supplementary Fig. 2a ) and performed Kaplan-Meier (KM) analyses with five TCGA datasets including that for breast cancer ( Supplementary Fig. 2b) , and a combined pool of the data for five top cancers, including liver cancer, lung cancer, non-small-cell lung carcinoma and bladder cancer ( Supplementary Fig. 2c ). Patients with breast cancer who had MLL3 PHD mutations had shorter disease-free survival times than patients with wild-type MLL3 (hereafter referred to as MLL3 WT ) or patients with mutations in sequences outside those encoding the PHD domain ( Supplementary Fig. 2b) . In a KM analysis using the pooled data from the five tumor types, we observed the same correlation between the MLL3 PHD mutation and patient survival ( Supplementary Fig. 2c ). Collectively, our analysis suggested that MLL3 PHD mutations disrupted a crucial function of this tumor suppressor protein and predicted decreased survival. Our biochemical studies demonstrated that the MLL3 PHD repeats interact with the BAP1 complex (Fig. 1) ; therefore, we investigated genetic alterations of BAP1 in MLL3
WT and MLL3-mutated patient samples. To this end, we used TCGA datasets for human breast cancer (n = 2,051) and pan lung cancer (n = 985). MLL3 was found to be mutated in 11.847% of breast cancer cases and in 15.736% of lung cancer cases ( Supplementary Fig. 2d ), whereas BAP1 had mutations in 1.804% of breast cancer cases and in 1.523% of lung cancer cases ( Supplementary Fig. 2e ).
To map the precise BAP1-binding peptide sequences within MLL3, we generated multiple Flag-tagged constructs expressing truncations of the MLL3-NTD (Fig. 2a) . By co-immunoprecipitation (co-IP) analyses, we found that the BAP1 complex bound to PHD repeats 2-4 of the first PHD repeat cluster (Fig. 2b) . Conversely, truncation of PHD fingers 2-4 completely blocked BAP1 binding (Fig. 2c) . We identified all reported mutations within the sequence encoding MLL3 PHD repeats 2-4 in pooled human cancers (Fig. 2d) . This region was found to be highly mutated, with 56% (28/50 amino acids) of the MLL3 amino acids altered across human cancers (Supplementary Table 2 ). Notably, a number of these mutations lead to substitution of highly conserved cysteine and histidine residues that are required for zinc binding 31 . On the basis of these observations, we hypothesized that mutations within MLL3 PHD might abrogate MLL3 PHD finger interactions with the BAP1 tumor suppressor complex. To test this hypothesis, we introduced human-cancer-associated point mutations into the MLL3-NTD-F3 construct and purified the mutant proteins from HEK293T cells (Fig. 2e) . Many cancer-associated MLL3 PHD alterations affected BAP1 complex binding; in particular Gly368Val, Trp383Leu, Cys388Tyr and His414Tyr strongly disrupted such interactions (Fig. 2e) . Using a human breast cancer cell line, CAL51, we confirmed that these point mutations resulted in a strongly diminished interaction between BAP1 and MLL3-NTD (Fig. 2f) .
To investigate whether PHD-domain mutations were enriched in specific cancer types, we analyzed the distribution of somatic mutations in MLL3 by using a combined cohort of TCGA datasets across 32 cancer types. MLL3 PHD mutations and overall MLL3 mutations were found to be enriched in lung adenocarcinoma (LUAD), bladder carcinoma (BLCA), breast cancer (BRCA) and colon adenocarcinoma (COAD) cancer types (Fig. 2g) . Mutations that resulted in inhibition of MLL3-BAP1 interaction were most enriched in lung cancer, accounting for 50% of cases (7/14; LUSC, n = 3; LUAD, n = 4) (Fig. 2h) . Loss of BAP1 protein is observed in various human cancers 32 , and Bap1-knockout mice show myeloid transformation 33 . Our data suggested that MLL3-PHD-BAP1 interactions had a crucial function that was disrupted in cancer, and they implicated BAP1 as a previously uncharacterized regulator of MLL3 COMPASS function.
BAP1 regulates MLL3 recruitment to enhancer chromatin. To investigate the functional connection between MLL3 and BAP1 on chromatin, we generated polyclonal antibodies to both proteins ( Supplementary Fig. 3a,b) . To confirm the specificity of our antibodies, we constructed BAP1-knockout cells (hereafter referred to as BAP1-KO cells) by using the CRISPR-Cas9 gene-editing system to delete BAP1 exons 4 and 5, which resulted in a reading-frame shift ( Supplementary Fig. 3c ). After confirming BAP1 deletion by mRNA and protein analysis ( Supplementary Fig. 3d ,e), we tested the specificity of our antibodies in chromatin immunoprecipitation followed by sequencing (ChIP-seq) analyses on WT cells, BAP1-null cells and MLL3-depleted cells (generated by using short hairpin RNAs (shRNAs) to knockdown MLL3 expression), and we observed specific reduction of signals for MLL3 and BAP1 in the respective knockout or knockdown lines ( Supplementary Fig. 3e-h) .
Analysis of ChIP-seq data using our MLL3-specific and BAP1-specific antibodies in human breast cancer cells revealed a total of 21,527 significant MLL3 peaks and 8,952 significant BAP1 peaks (Fig. 3a) . About 60% of MLL3 binding sites were localized to enhancers, which was consistent with our observations for the Drosophila Articles NATURe MeDiCiNe MLL3 homolog, Trr 20 ( Fig. 3a) . Of note, 50% of BAP1 peaks were similarly located at intergenic regions and introns (Fig. 3b) , and 7,491 (83%) of BAP1-occupied regions were co-occupied by MLL3 (Fig. 3c,d ). Motif enrichment analysis of both the MLL3 and BAP1 peaks demonstrated an enrichment of ETS-like transcription-factor-binding motifs ( Supplementary Fig. 4a ).
Colocalization of MLL3 and BAP1 on chromatin suggested that MLL3 recruitment to enhancers might involve interactions with 
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HEK293T cells IP from whole-cell lysates was performed with antibodies directed against the Flag epitope, followed by immunoblotting (IB) with antibodies directed against BAP1 or ASXL2. The KMT EZH2 was used as negative control. e, IP of endogenous MLL3, MLL4, SET1A or SET1B from HEK293T cells followed by immunoblotting for BAP1 and ASXL2. The core COMPASS subunit RBBP5, and a subunit specific to the MLL3 and MLL4 COMPASS branches, UTX, were used as positive controls. An EZH2-specific IP reaction served as a negative control. f, IP of endogenous BAP1 from HEK293T cells followed by immunoblotting for SET1A, SET1B, MLL3 and MLL4. Images for all panels are representative of at least two independent experiments. Uncropped images are available in Supplementary Fig. 11 . Pol ll H3K27Ac BAP1 WT and BAP1-KO cells with antibodies to BAP1, MLL3, ubiquitinated Lys119 of histone H2A (H2AK119Ub), H3K4me1 and H3K4me3. Occupancy levels for each protein or histone modification were aligned to the BAP1 peaks and divided into five clusters (Fig. 3e) . Loss of the H2AK119 deubiquitinase BAP1 resulted in increased levels of monoubiquitinated H2AK119 (H2AK119Ub or H2AUb) specifically at clusters 1 and 2 (group1 peaks) (Fig. 3e) , which exhibited an active enhancer signature (defined as a relatively high H3K4me1 to H3K4me3 ratio as compared to that at active promoters) and the presence of acetylated H3K27 (H3K27ac). These results suggested that the BAP1 complex functioned at enhancers and could modulate the activity of MLL3 COMPASS. In support of this hypothesis, violin plot analysis indicated that most of the group1 BAP1 peaks were located at potential enhancers (Fig. 3f) . Notably, MLL3 occupancy and levels of H3K4me1 were reduced in BAP1-KO cells, particularly at group1 peaks (Fig. 3g,e and Supplementary Fig. 4b,c) ; by contrast, H3K4me3 levels were not detectably altered (Fig. 3e) . BAP1 depletion from enhancers that were normally highly occupied by MLL3 resulted in increased levels of H2AUb, whereas MLL3 occupancy and H3K4me1 levels were reduced (Fig. 3h) . However, at promoter regions at which there was minimal MLL3 binding, loss of BAP1 led to an increased H2AUb signal but dis not affect H3K4me1 levels (Fig. 3i) . ChIP-qPCR was performed to quantify these occupancy changes for BAP1, H2AUb, MLL3, H3K4me1 and H3K4me3 at BAP1 target sites at the chloride intracellular channel 5 (CLIC5) enhancer and the biotinidase (BTD) promoter ( Supplementary Fig. 4d ,e). Our results suggest that BAP1 functions in a context-dependent manner at promoters and enhancers. Gene Ontology (GO) pathway analysis demonstrated that genes near group 1 peaks were involved in a range of developmental processes ( Supplementary Fig. 4f ). Taken together, these results demonstrate that BAP1 is required for efficient recruitment of MLL3 COMPASS H3K4 monomethyltransferase activity to enhancers.
MLL3 COMPASS regulates tumor suppressor gene expression through BAP1-dependent enhancers.
To investigate whether MLL3 loss at enhancers altered the expression of nearby genes, we generated cells lacking MLL3 by using CRISPR-Cas9 gene editing. To control for off-target effects, we used two independent sets of single guide RNAs (sgRNAs) to eliminate either exon 2 or exon 8, which in both cases caused a reading-frame shift ( Fig. 4a and Supplementary Fig. 5a,b) . MLL3 protein was absent in our knockout clones, as assessed by western blotting (Fig. 4b and Supplementary  Fig. 5c ), and the MLL3-specific antibodies did not co-immunoprecipitate BAP1 or RBBP5 (a core subunit of the COMPASS family) in these cells (Fig. 4c) . We performed ChIP-seq and RNA sequencing (RNA-seq) analyses in parental CAL51 cells, BAP1-KO and MLL3-KO cells. Loss of BAP1 expression resulted in reduced levels of MLL3 and H3K4me1 occupancy at group 1 loci, which correlated with changes in the expression of nearby genes ( Fig. 4d and Supplementary Fig. 5d-f) . By RNA-seq analysis, we found that 333 protein-coding genes were consistently downregulated (P < 0.01) and 120 protein-coding genes were upregulated in MLL3-deficient cells (Fig. 4e and Supplementary Table 3) . Notably, 140 proteincoding genes were downregulated (P < 0.01, fold change > 2) in all three MLL3-deficient cells (Supplementary Table 4) , whereas only seven genes were consistently upregulated. This suggests that BAP1-dependent MLL3 recruitment to enhancers predominantly positively regulates gene expression.
We also evaluated whether MLL3 regulated BAP1-chromatin binding. BAP1 occupancy was not altered in MLL3-KO cells, suggesting that BAP1 can bind chromatin independently of the MLL3 complex (Supplementary Fig. 5g ). Pathway analysis by Metascape 34 demonstrated that genes downregulated after MLL3 loss were enriched for epithelial cell differentiation pathway function ( Supplementary Fig. 6a and Supplementary Table 5 ). This suggested that MLL3 deficiency could disrupt normal epithelial differentiation and lead to malignant migratory phenotypes through increased epithelial-mesenchymal transition (EMT). For instance, expression of the transcription factor GRHL2, which suppresses oncogenic EMT in breast cancer 35 , was almost completely silenced in MLL3-KO cells. Gene set enrichment analysis (GSEA) also indicated similar pathway enrichment for genes downstream of MLL3 function (Supplementary Table 6 ). We then asked whether MLL3 and BAP1 regulated a common set of genes and found that MLL3 and BAP1 positively co-regulated the expression of 50 genes (P < 0.01; fold change > 2) (Fig. 4f and Supplementary Table 7) .
Of note, many of the downregulated genes in both Fig. 4f and Supplementary Fig. 6b,c) . We confirmed downregulation of mRNA expression for ITM2A, DACT2 and FRZB using real-time PCR analysis (Fig. 4g) . According to Metascape analysis, epithelial cell differentiation was the most enriched pathway that was downregulated after loss of MLL3 and BAP1 expression ( Supplementary Fig. 6d ). Consistent with this observation, depletion of MLL3 promoted cell growth and colony-formation ability in vitro ( Supplementary Fig. 6e,f) . Moreover, loss of MLL3 significantly accelerated tumor growth in vivo and shortened animal survival (Fig. 4h,i) .
UTX, a component of MLL3-COMPASS, is bound to enhancers in a BAP1-dependent manner. Recent studies have addressed the relationship between BAP1 and PRC2 expression in cancer [42] [43] [44] . Deletion of BAP1 in mouse bone marrow results in increased expression of the histone KMT EZH2 and increased amounts of H3K27me3. However, in human uveal melanoma (UM), EZH2 levels are not affected by BAP1 loss. Therefore, the context and mechanism through which BAP1 affects PRC2 expression and H3K27me3 levels are likely to be cell-type specific. Because UTX is a core subunit of MLL3 COMPASS 11, 13 , we hypothesized that BAP1 might also be involved in controlling UTX's H3K27me3 demethylase activity at enhancers.
To explore the potential connection between BAP1 and UTX, we assayed H3K27me3 levels in our BAP1
WT and BAP1-KO cells. H3K27me3 levels were increased in BAP1-KO cells (Fig. 5a) , consistent with previous studies. Unexpectedly, we found that the levels of the PRC2 subunits EZH2 and SUZ12 were not significantly increased as the result of BAP1 loss (Fig. 5a ). By contrast, UTX protein levels were reduced in BAP1-KO cells (Fig. 5a ). This effect was reproducible in another breast cancer line (MCF7), using shRNAs targeting BAP1 (Fig. 5b) . RNA-seq analysis demonstrated that EZH2 and KDM6A (UTX) mRNA levels were not altered by BAP1 depletion ( Supplementary Fig. 7a,b) . Therefore, the increased H3K27me3 observed in BAP1-KO cells was not the result of increased PRC2 expression but rather due to diminished UTX occupancy as the result of loss of MLL3 COMPASS interaction with chromatin.
To determine the effect of BAP1 loss on UTX chromatin occupancy, we generated antibodies to UTX ( Supplementary Fig. 7c-h ). We analyzed chromatin occupancy for UTX, SUZ12 and H3K27me3 in BAP1
WT and BAP1-KO cells ( Fig. 5c and Supplementary Fig. 7i ). Loss of BAP1 resulted in increased H3K27me3 levels, as detected by ChIP-seq, at group 1 loci, where MLL3 occupancy was most strongly diminished (Fig. 3g) . Notably, increased H3K27me3 levels correlated with loss of UTX binding, whereas the occupancy of the SUZ12 subunit of PRC2 was unchanged at these sites ( Fig. 5c and Supplementary Figs. 7j and 8a) .
RNA-seq analysis revealed that UTX-KO cells had similar changes in gene expression to those of MLL3-KO and BAP1-KO cells, with downregulation of genes in group 1 (Fig. 5d, left) . In total, there were 27 protein-coding genes co-regulated by MLL3, UTX WT and three independent MLL3-KO cells, as assessed by immunoblotting (n = 3). HSP90 was used as a loading control. c, The interaction between MLL3 and BAP1 in cell lysates from MLL3 WT and two MLL3-KO clones, as assessed by IP followed by immunoblotting (n = 3). The core COMPASS subunit RBBP5 was used as a control. d, Left and middle, heat maps showing log 2 (fold changes) of the occupancy levels of BAP1, H2AUb, MLL3, H3K4me1 and H3K4me3 between BAP1-KO and BAP1
WT cells (left) and between MLL3-KO and MLL3
WT cells (middle). Results are representative of two replicates. Rows are ordered as in c. Right, the log 2 (fold change) of nearby gene expression in BAP1-KO cells or MLL3-KO cells, as compared to that in WT cells (n = 2). e, Heat map showing the common differentially expressed genes in three different MLL3-KO clones. There were two replicates each. f, Venn diagram showing genes that are downregulated by loss of MLL3 and/or BAP1 (P < 0.01 by two-tailed unpaired t-test; fold change > 2) (n = 2). Examples of tumor suppressors are shown. g, Expression levels of ITM2A, DACT2 and FRZB, as assessed by real-time PCR in WT, MLL3-KO and BAP1-KO cells (n = 3 independent experiments). Data are presented as mean ± s.d. **P < 0.01 by two-tailed unpaired Student's t-test. h, Left, photographs of nude mice (top) and fat pads taken from these mice (bottom), into which 4 × 10 6 of MLL3 WT or MLL3-KO breast cancer cells were inoculated into the fat pad. Scale bar, 1 mm. Right, tumor growth in animals at 40 d after inoculation (n = 10 per group). Horizontal bars indicate the mean of each group. P value was determined by a log-rank (Mantel-Cox) test. i, Animal survival at the indicated times after inoculation. A two-tailed unpaired Student's t-test was used for statistical analysis. Images for all panels are representative of at least two independent experiments. Uncropped images are shown in Supplementary Fig. 13 . Anti-HSP90 
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NATURe MeDiCiNe and BAP1 that exhibited more than a twofold change in the knockout cells (Supplementary Table 8 ). To test whether H3K27me3 was directly involved in controlling these co-regulated genes, we treated cells with the EZH2 inhibitor GSK126. Notably, EZH2 catalytic inhibition largely rescued the gene expression defects in the mutant cells (Fig. 5d, right) . We identified many tumor suppressor genes that were controlled by MLL3, BAP1 and UTX (Fig. 5e,f ). There were 3,858 genes associated with common MLL3, BAP1, H3K4me1 and H2Aub peaks, and all of the MLL3-BAP1 target genes were occupied by MLL3, BAP1 and the indicated histone marks (Fig. 5g) . The majority of MLL3 and BAP1 downstream genes were directly controlled by MLL3 and BAP1, and loss of BAP1 or MLL3 expression dramatically affected the histone modifications at those loci (Fig. 5h) . For instance, BAP1 loss led to decreased MLL3 and UTX occupancy at the enhancers of the GRHL2 gene, which was coincident with increased H3K27me3 levels ( Fig. 5i and Supplementary  Fig. 8b-d ) and decreased gene expression (Fig. 5j) . ChIP-seq analysis confirmed that UTX depletion increased H3K27me3 levels at the enhancers of these tumor suppressor genes ( Supplementary  Fig. 8e-h ). These results were further validated by ChIP-qPCR ( Supplementary Fig. 8i,j) . These results suggest that BAP1 influences UTX stability through an interaction mediated via the MLL3 PHD repeats.
To investigate the relationship between MLL3, BAP1 and UTX, we performed size-exclusion chromatography analyses 45 with nuclear extracts isolated from MLL3
WT and MLL3-KO cells. As predicted by our purifications, BAP1 co-eluted with UTX protein in fractions 20-23, with the peak at fraction 21 ( Supplementary  Fig. 9a ). However, an MLL3 deficiency resulted in an altered BAP1 elution profile (toward smaller-sized fractions) from the sizeexclusion column in fractions 21-25, with the peak in fraction 23 ( Supplementary Fig. 9a) . Furthermore, the BAP1 complex was also observed as a top interactor with Flag-tagged UTX in HEK293T cells (Supplementary Fig. 9b) . Lastly, depletion of MLL3, but not MLL4, affected the interactions between UTX and BAP1 ( Supplementary  Fig. 9c-f) .
Resetting the epigenetic balance of gene expression in MLL3
PHD mutant cancer cells. We observed that inhibition of EZH2 catalytic activity restored the expression of many genes that were downregulated by depletion of MLL3, UTX or BAP1 (Fig. 5d, right) . Indeed, approximately 80% of the genes downregulated in MLL3-KO cells were rescued by GSK126 treatment (Fig. 6a) , suggesting they were direct PRC2 target genes. Expression of two tumor suppressor genes, FRZB and GRHL2, which were silenced in MLL3-KO cells, were fully rescued by GSK126 treatment (Fig. 6b) . Furthermore, H3K27me3 levels were increased at the vast majority of MLL3 target genes after MLL3-KO (Fig. 6c) and were reduced again after GSK126 treatment (Fig. 6d and Supplementary Fig. 10a ).
We therefore hypothesized that PRC2 inhibition might be a useful therapeutic tool to reset the loss in the Polycomb-and COMPASSbalanced state of gene expression at these loci in MLL3-mutant cancer cells. Indeed, loss of MLL3 significantly sensitized tumor cells to EZH2 inhibition (Fig. 6e-g and Supplementary Fig. 10b ). To investigate the drug sensitivity of other tumor cells containing MLL3 mutations, we used a breast cancer cell line, MDA-MB-453, which contains a heterozygous MLL3 PHD mutation (Cys385Tyr) that disrupts interaction of MLL3 with BAP1 ( Supplementary  Fig. 10c,d) . Notably, we found that even in the heterozygous cells the interaction between MLL3 and BAP1 was largely reduced (Supplementary Fig. 10e ). GSK126 treatment of MLL3 WT (CAL51) and MLL3-mutated (MDA-MB-453) cells revealed that mutational status correlated with increased GSK126 sensitivity (Fig. 6h-k and Supplementary Fig. 10f ).
To establish a direct link between MLL3 PHD mutations and EZH2 inhibitor sensitivity, we used CRIPSR-Cas9 to gener- , as determined by cell counting. 10 5 cells were seeded in 6-well plates and cultured for the indicated times in the presence of DMSO or GSK126. Data are presented as mean ± s.d. of n = 3 independent experiments; P value was determined by a two-tailed unpaired t-test. j, Cell viability of CAL51 and MDA-MB-453 cells that were treated with the indicated concentrations of GSK126 for 8 d, as determined by cell counting. The culture medium and drug were replaced every 2 d. Data are presented as mean ± s.d. of n = 3 independent experiments. **P < 0.01; *P < 0.05 by a two-tailed unpaired Student's t-test. k, 10 4 of CAL51 cells (MLL3-WT) and MDA-MB-453 (MLL3-C385Y) cells were seeded in a 6-well plate and cultured for 2 weeks in the presence of DMSO or GSK126. Colony-forming ability of the cells was determined by crystal violet staining. Data are presented as mean ± s.d. of n = 3 independent experiments. **P < 0.01 by a two-tailed unpaired Student's t-test. l, The ranked dependency (or sensitivity) reflects the impairment of growth and survival of cancer cells due to the inactivation of EZH2, SUZ12 and EED function in three different breast cancer cell lines, MDA-MB-453 (MLL3 PHD mutation), MDA-MB-463 (MLL3 WT ) and T47D (MLL3 non-PHD-domain mutation). The sensitivity score was calculated from the data downloaded from the Project Drive (Methods). m,n, Tumor size after inoculation of 4 × 10 6 of MLL3 WT of MLL3-KO breast cancer cells into the fat pad of nude mice. Two weeks after transplantation, the animals were treated with either PBS or GSK126 (50 mg/kg) for 10 d. Tumor size at day 40 after transplantation (n = 10) (m) and animal survival at the indicated times after inoculation (n) are shown. Statistical analysis was done using a log-rank (Mantel-Cox) test (m) or a two-tailed unpaired Student's t-test (n). o, Model. BAP1 controls tumor suppressor gene expression by binding to enhancer chromatin and removing H2AUb to facilitate transcription. The BAP1 complex recruits MLL3 COMPASS to enhancers and catalyzes the formation of H3K4me1. Moreover, the UTX subunit within MLL3 COMPASS is stabilized by BAP1 and removes H3K27me3 at enhancers of the indicated genes. In cancers bearing mutations in the PHD-domain-encoding region in MLL3, the MLL3 COMPASS complex, including the H3K27me3 demethylase UTX, is not recruited to BAP1-dependent enhancers, leading to increased H3K27me3 and resulting in the silencing of tumor suppressors such as FRZB, GRHL2 and DACT2. In MLL3-mutant cancer cells, EZH2 inhibition reduces the H3K27me3 levels and resets tumor suppressor expression. Fig. 10g ). The interaction between BAP1 and the mutant MLL3 was largely reduced in these cells ( Supplementary Fig. 10h ), which was consistent with our observations in MDA-MB-453 cells. To investigate whether mutations within MLL3 PHD also contributed to gene expression silencing, we performed RNA-seq analysis in MLL3 WT ,
MLL3
Gly368Val and
Trp383Leu cells. We found that there were 484 genes significantly downregulated, and only 41 genes upregulated, in common to both knock-in cell lines ( Supplementary Fig. 10i,j) , which was consistent with our previous finding that MLL3 functioned primarily as an activating factor (Fig. 4e) . Consistent with these decreases in gene expression, point mutations within MLL3 PHD led to a global increase of H3K27me3 at non-transcription start site (non-TSS) regions Fig. 10k ). We also compared the gene expression profile between MLL3-KO and MLL3-knock-in cells and found that the gene expression profiles were similar (Supplementary Fig. 10l ). These results suggested that mutations in the PHD-domainencoding region could lead to loss of function of MLL3. Moreover, the MLL3 Gly368Val -expressing and MLL3
Trp383Leu
-expressing HEK293T cells were more sensitive to EZH2 inhibitor treatment than the cells expressing MLL3
WT (Supplementary Fig. 10m ). We retrieved cancer dependency and synthetic lethal relationship data from Project Drive 46 and calculated the dependency of the PRC2 subunits EZH2, SUZ12 and EED in three different breast cancer cell lines-MDA-MB-453 (MLL3 PHD mutation), MDA-MB-463 (MLL3 WT ) and T47D (MLL3 non-PHD-domain mutation). Cells with a mutation in MLL3 PHD were more sensitive to the depletion of all the three PRC2 components than cells expressing MLL3
WT or MLL3 with a non-PHD-domain mutation (Fig. 6l) .
We next tested whether MLL3 WT cancer cells, which were resistant to EZH2 inhibitor treatment in vitro but became drug-sensitive after MLL3 depletion (Fig. 6e) , exhibited similar properties in an animal model. We injected MLL3 WT -expressing and MLL3-depleted cells in nude mice and treated the mice with GSK126 in vivo. Treatment of mice with MLL3-deficient cells with the EZH2 inhibitor significantly reduced tumor size and extended overall survival (Fig. 6m,n) . Taken together, our result suggests that in mammals, BAP1 controls the expression of tumor suppressor genes by binding to enhancer chromatin and removing H2AUb to facilitate transcription (Fig. 6o, top) . The BAP1 complex recruits MLL3 COMPASS through interactions with its PHD domain to enhancers to catalyze H3K4me1 formation. Moreover, the UTX subunit within MLL3 COMPASS is stabilized by BAP1 and further removes H3K27me3 at the indicated enhancers (Fig. 6o, top) . Under this wild-type situation, the activities of PRC2, MLL3 COMPASS and the BAP1 complex at enhancer chromatin can be considered balanced (Fig. 6o,  top) . In cancers with mutations in the MLL3 PHD domain (Fig. 6o,  middle) , the complex is not recruited to BAP1-dependent enhancers, and the absence of UTX on chromatin results in an unbalanced epigenetic state of enhancer chromatin via increased H3K27me3 levels on these loci and silencing of tumor suppressors, such as RBMS3, GRHL2 and DACT2 (Fig. 6o, middle) . To balance the epigenetic state of gene expression in the MLL3-mutant cancer cells, EZH2 inhibition reduces the H3K27me3 levels and resets tumor suppressor expression (Fig. 6o, bottom) . We propose that this approach is a promising therapeutic tool for regulating the balanced state of gene expression in cancers caused as the result of mutations in the genes encoding COMPASS or PRC2 subunits.
Discussion
Here we defined a previously uncharacterized chromatin-based tumor suppressor pathway linking MLL3-and UTX-containing COMPASS with the BAP1 and ASXL complex and provided a therapeutic approach for the treatment of cancers caused as the result of mutations in genes encoding the subunits of these complexes. We found that cancer hotspot mutations in the region encoding the MLL3 N-terminal PHD repeats disrupted MLL3 association with the BAP1 complex and resulted in reduced MLL3 and UTX recruitment to enhancers, leading to misregulation of the epigenetic chromatin state at these loci. Thus, MLL3
PHD mutations expose a vulnerability to EZH2 inhibitor therapy through de-repression of tumor suppressors.
Our study reveals a number of intriguing aspects regarding the role of the MLL3 and MLL4 branches of the COMPASS family in human cancer. For instance, the region encoding MLL4's SET domain is highly mutated in human cancer; however, not all of these mutations significantly reduce MLL4 catalytic activity 18, 19 . This situation parallels the MLL3 mutations examined in this study, where not all of the mutations abrogated binding between MLL3 and the BAP1 complex (Fig. 2) . In fact, the crystal structure (Protein Data Bank (PDB) ID: 2YSM) of MLL3 PHD repeats 2-3 revealed that the mutations important for MLL3-BAP1 complex binding, were closely associated with zinc atoms, which help maintain the structure of the PHD fingers ( Supplementary Fig. 10n) .
Notably, BAP1 selectively associates with MLL3, but not with MLL4, indicating a bifurcation in the function of these complexes. Future experiments will address whether these differences reflect tissue-specific functions or whether perhaps MLL4 recruits as yet uncharacterized cofactors to mediate BAP1-like activities. Of note, a very recent study reported that the kinase AKT1 binds to the MLL4 PHD domain and phosphorylates Ser1,331 of MLL4 47 . Phosphorylation of the PHD domain affects MLL4 catalytic activity, but not MLL4 occupancy, at chromatin, indicating that the function of the MLL3 and MLL4 PHD domains may be distinct. Nevertheless, our studies suggest that modifications or mutations within the PHD-domain-encoding region of MLL3 or MLL4 COMPASS can affect H3K4me1 levels and enhancer activity through different mechanisms.
Comparison of gene expression changes in MLL3-mutant, BAP1-mutant and UTX-mutant cancer cells revealed a notable overlap in target genes. In particular, several tumor suppressor genes were all positively co-regulated by these three factors. In our model (Fig. 6o) , MLL3 COMPASS is recruited to its targets through interactions with BAP1. Therefore, how the BAP1 complex is specifically targeted to these tumor suppressors is an important question. According to our motif analysis, we found both MLL3-and BAP1-enriched motifs were similar to the ETS motif, which was consistent with previous studies 33 . These findings suggest that ETS family factors have a role in recruiting the complex in the context of multiple cancer types.
Our study identifies an MLL3-UTX-PRC2 regulatory axis as a target for therapeutic treatment through small-molecule EZH2 inhibition. Notably, both EZH2 and the MLL3 genes reside on chromosome 7q36, a region (7q36) that is frequently gained or amplified in multiple human cancers 48 . Indeed, according to Cbio 49, 50 analysis, EZH2 and MLL3 genes are usually co-amplified in numerous human cancers. These observations further support the possibility of EZH2 as a therapeutic target for MLL3-mutant cancers and points to a potential role for EZH2 inhibition therapy in cancers harboring mutant COMPASS subunits by resetting the Polycomband COMPASS-balanced state of gene expression.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0034-6.
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Data exclusions
Describe any data exclusions. In Figure 4 , two mice injected with MLL3-WT cells and one mouse injected with MLL3-KO cells were sacrificed for tumor unrelated problems and therefore excluded from the study. In Figure 6 , one mice injected with MLL3-KO treated with PBS and one mice injected with MLL3-WT cells treated with GSK126 died immediately after the end of the vehicle administration therefore they were excluded from the study.
Replication
Describe whether the experimental findings were reliably reproduced. For all in vivo and in vitro study, the findings were reliably reproduced
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For our animal study, mice were randomly assigned to treated or control group. Refer to Methods/Animal experiments
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The group allocation and outcome were assigned by an animal technician not aware of the expected results.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
